Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 10/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 10/20 | 0.45 |
| ▸ | CA12 | O43570 | 6/20 | 0.44 |
| ▸ | CA1 | P00915 | 6/20 | 0.44 |
| ▸ | CA2 | P00918 | 6/20 | 0.44 |
| ▸ | CA9 | Q16790 | 6/20 | 0.44 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PSMD11 | O00231 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15613188 | 1.00 | HSP90AA1 (0.45) | HSP90AA1HSP90AB1CA12CA1CA2 | |
| SCHEMBL15525934 | 1.00 | HSP90AA1 (0.45) | HSP90AA1HSP90AB1CA12CA1CA2 | |
| SCHEMBL15613111 | 0.98 | SENP1 (0.44) | HSP90AA1HSP90AB1CA12CA1CA2 | |
| SCHEMBL16731416 | 0.98 | SENP1 (0.44) | HSP90AA1HSP90AB1CA12CA1CA2 | |
| SCHEMBL16713218 | 0.98 | SENP1 (0.44) | HSP90AA1HSP90AB1CA12CA1CA2 | |
| SCHEMBL15526242 | 0.97 | HSP90AA1 (0.42) | HSP90AA1HSP90AB1CA12CA1CA2 | |
| SCHEMBL28343540 | 0.95 | HSP90AA1 (0.44) | HSP90AA1HSP90AB1CA12CA1CA2 | |
| SCHEMBL23134912 | 0.91 | HSP90AB1 (0.45) | HSP90AA1HSP90AB1 | |
| SCHEMBL20820234 | 0.91 | HSP90AA1 (0.45) | HSP90AA1HSP90AB1 | |
| SCHEMBL18844594 | 0.90 | HSP90AB1 (0.44) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10828315-B2 | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200316090-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. | 2020-10-08 | — | — | US | disclosed |
| US-10675360-B2 | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-9956293-B2 | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170128580-A1 | TARGETED THERAPEUTICS | TARVEDA THERAPEUTICS, INC. | 2017-05-11 | — | — | US | disclosed |
| US-9597343-B2 | Targeted therapeutics | SYNTA PHARMACEUTICALS CORP. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20170056510-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170049899-A1 | TARGETED THERAPEUTICS | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200316090-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | HSP90AA1 5/4885HSP90AB1 2/4885CA12 4105/4885 |
| US-20170128580-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | HSP90AA1 5/4885HSP90AB1 2/4885CA12 4105/4885 |
| US-20170049899-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | HSP90AA1 5/4885HSP90AB1 2/4885CA12 4105/4885 |
| US-10675360-B2 | Targeted therapeutics | CDC37, HSP90AB1, HSP90B1 | HSP90AA1 5/4885HSP90AB1 2/4885CA12 4105/4885 |
| US-10828315-B2 | Targeted therapeutics | CDC37, HSP90AB1, HSP90B1 | HSP90AA1 5/4885HSP90AB1 2/4885CA12 4105/4885 |
| US-20170056510-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | HSP90AA1 5/4885HSP90AB1 2/4885CA12 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.